tetano
Editor, Senior Moderator
Sci Bull (Beijing)
. 2023 Oct 4:S2095-9273(23)00683-7.
doi: 10.1016/j.scib.2023.09.048. Online ahead of print. Classification of five SARS-CoV-2 serotypes based on RBD antigenicities
Shixiong Hu[SUP] 1 [/SUP], Chunli Wu[SUP] 2 [/SUP], Xinkai Wu[SUP] 3 [/SUP], Xuehui Ma[SUP] 4 [/SUP], Chang Shu[SUP] 5 [/SUP], Qian Chen[SUP] 6 [/SUP], Anqi Zheng[SUP] 4 [/SUP], Huiting Yang[SUP] 4 [/SUP], Jian Lu[SUP] 7 [/SUP], Pei Du[SUP] 8 [/SUP], George Fu Gao[SUP] 9 [/SUP], Qihui Wang[SUP] 10 [/SUP]
Affiliations
The continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a significant number of variants, particularly with the emergence of Omicron with many sub-variants. These variants have exhibited increased immune escape, leading to reduced efficacy of existing vaccines and therapeutic antibodies. Given the diminished cross-neutralization observed among these variants, it is plausible that SARS-CoV-2 has developed multiple serotypes. As the major antigenic site, the receptor-binding domain (RBD) of viral spike (S) protein was chosen for serotyping. We selected 23 representative variants, including pre-Omicron variants and Omicron sub-variants, and classified them into five serotypes based on systematic evaluation of the antigenicities of their RBDs. Each serotype includes several genetically distinct variants. Serotype-I encompasses all pre-Omicron variants (with two subtypes), while the remaining four serotypes are all comprised of Omicron sub-variants at different stages of evolution. We propose that these serotypes can serve as a foundation for rapid classification of newly emerging SARS-CoV-2 variants, and guide the development of future broad-spectrum vaccines and neutralizing antibodies against the coronavirus disease 2019 (COVID-19).
Keywords: Receptor-binding domain (RBD); SARS-CoV-2; Serotype classification; Spike (S); mRNA vaccine.
. 2023 Oct 4:S2095-9273(23)00683-7.
doi: 10.1016/j.scib.2023.09.048. Online ahead of print. Classification of five SARS-CoV-2 serotypes based on RBD antigenicities
Shixiong Hu[SUP] 1 [/SUP], Chunli Wu[SUP] 2 [/SUP], Xinkai Wu[SUP] 3 [/SUP], Xuehui Ma[SUP] 4 [/SUP], Chang Shu[SUP] 5 [/SUP], Qian Chen[SUP] 6 [/SUP], Anqi Zheng[SUP] 4 [/SUP], Huiting Yang[SUP] 4 [/SUP], Jian Lu[SUP] 7 [/SUP], Pei Du[SUP] 8 [/SUP], George Fu Gao[SUP] 9 [/SUP], Qihui Wang[SUP] 10 [/SUP]
Affiliations
- PMID: 37919162
- DOI: 10.1016/j.scib.2023.09.048
The continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a significant number of variants, particularly with the emergence of Omicron with many sub-variants. These variants have exhibited increased immune escape, leading to reduced efficacy of existing vaccines and therapeutic antibodies. Given the diminished cross-neutralization observed among these variants, it is plausible that SARS-CoV-2 has developed multiple serotypes. As the major antigenic site, the receptor-binding domain (RBD) of viral spike (S) protein was chosen for serotyping. We selected 23 representative variants, including pre-Omicron variants and Omicron sub-variants, and classified them into five serotypes based on systematic evaluation of the antigenicities of their RBDs. Each serotype includes several genetically distinct variants. Serotype-I encompasses all pre-Omicron variants (with two subtypes), while the remaining four serotypes are all comprised of Omicron sub-variants at different stages of evolution. We propose that these serotypes can serve as a foundation for rapid classification of newly emerging SARS-CoV-2 variants, and guide the development of future broad-spectrum vaccines and neutralizing antibodies against the coronavirus disease 2019 (COVID-19).
Keywords: Receptor-binding domain (RBD); SARS-CoV-2; Serotype classification; Spike (S); mRNA vaccine.